Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 74.00K | 41.00K | 70.00K | ||
| Total Receivables | 27.00K | 23.00K | 11.00K | ||
| Inventory | -- | -- | -- | ||
| Prepaid Expenses | 16.00K | 23.00K | 16.00K | ||
| Finance Division Loans and Leases Current | -- | -- | -- | ||
| Total Finance Division Other Current Assets | -- | -- | -- | ||
| Other Current Assets | 536.00K | 536.00K | 528.00K | ||
| Total Current Assets | 653.00K | 623.00K | 625.00K | ||
|
|
|||||
| Total Current Assets | 653.00K | 623.00K | 625.00K | ||
| Net Property, Plant & Equipment | 1.00K | 1.00K | 2.00K | ||
| Long-term Investments | -- | -- | -- | ||
| Goodwill | -- | -- | -- | ||
| Total Other Intangibles | -- | -- | -- | ||
| Finance Div Loans & Leases LT | -- | -- | -- | ||
| Total Finance Div Other LT Assets | -- | -- | -- | ||
| Total Other Assets | -- | -- | -- | ||
| Total Assets | 654.00K | 624.00K | 627.00K | ||
|
|
|||||
| Total Accounts Payable | 4.12M | 4.31M | 3.02M | ||
| Total Accrued Expenses | 28.00K | -- | 27.00K | ||
| Short-term Debt | 3.29M | 2.61M | 750.00K | ||
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | ||
| Finance Division Debt Current | -- | -- | -- | ||
| Total Finance Division Other Current Liabilities | -- | -- | -- | ||
| Total Other Current Liabilities | -- | -- | -- | ||
| Total Current Liabilities | 7.43M | 6.92M | 3.80M | ||
|
|
|||||
| Total Current Liabilities | 7.43M | 6.92M | 3.80M | ||
| Long-Term Debt | -- | -- | -- | ||
| Short-term Debt | 3.29M | 2.61M | 750.00K | ||
| Capital Leases | -- | -- | -- | ||
| Finance Division Debt Non Current | -- | -- | -- | ||
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | ||
| Total Other Liabilities | -- | -- | -- | ||
| Total Liabilities | 7.43M | 6.92M | 3.80M | ||
|
|
|||||
| Common Stock & APIC | 201.89M | 201.60M | 201.60M | ||
| Retained Earnings | -212.47M | -211.62M | -207.98M | ||
| Treasury Stock & Other | 3.81M | 3.72M | 3.21M | ||
| Total Common Equity | -6.78M | -6.30M | -3.17M | ||
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | ||
| Preferred Stock Non Redeemable | -- | -- | -- | ||
| Preferred Stock Convertible | -- | -- | -- | ||
| Preferred Stock, Others | -- | -- | -- | ||
| Total Preferred Equity | -- | -- | -- | ||
|
|
|||||
| Total Common Equity | -6.78M | -6.30M | -3.17M | ||
| Total Preferred Equity | -- | -- | -- | ||
| Total Minority Interest | -- | -- | -- | ||
| Total Equity | -6.78M | -6.30M | -3.17M | ||
|
|
|||||